Suppr超能文献

Syndecan-1的细胞质C末端片段通过顺序蛋白水解产生,并拮抗Syndecan-1依赖性肺肿瘤细胞迁移。

A cytoplasmic C-terminal fragment of Syndecan-1 is generated by sequential proteolysis and antagonizes Syndecan-1 dependent lung tumor cell migration.

作者信息

Pasqualon Tobias, Pruessmeyer Jessica, Jankowski Vera, Babendreyer Aaron, Groth Esther, Schumacher Julian, Koenen Andrea, Weidenfeld Sarah, Schwarz Nicole, Denecke Bernd, Jahr Holger, Dreymueller Daniela, Jankowski Joachim, Ludwig Andreas

机构信息

Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany.

Institute of Molecular Cardiovascular Research, RWTH Aachen University, Aachen, Germany.

出版信息

Oncotarget. 2015 Oct 13;6(31):31295-312. doi: 10.18632/oncotarget.5174.

Abstract

Syndecan-1 is a surface expressed heparan sulphate proteoglycan, which is upregulated by several tumor types and involved in tumor cell migration and metastasis. Syndecan-1 is shed from the cell surface and the remaining transmembrane fragment undergoes intramembrane proteolysis by γ-secretase. We here show that this generates a cytoplasmic C-terminal fragment (cCTF). In epithelial lung tumor A549 cells the endogenously produced cCTF accumulated when its proteasomal degradation was blocked with bortezomib and this accumulation was prevented by γ-secretase inhibition. Overexpression of the cCTF suppressed migration and invasion of A549 cells. This inhibitory effect was only seen when endogenous Syndecan-1 was present, but not in Syndecan-1 deficient cells. Further, overexpression of Syndecan-1 cCTF increased the basal activation of Src kinase, focal adhesion kinase (FAK) and Rho GTPase. This was associated with increased adhesion to fibronectin and collagen G and an increased recruitment of paxillin to focal adhesions. Moreover, lung tumor formation of A549 cells in mice was reduced by overexpression of Syndecan-1 cCTF. Finally, delivery of a synthetic peptide corresponding to the Syndecan-1 cCTF suppressed A549 cell migration and increased basal phosphorylation of Src and FAK. Our data indicate that the Syndecan-1 cCTF antagonizes Syndecan-1 dependent tumor cell migration in vitro and in vivo by dysregulating proadhesive signaling pathways and suggest that the cCTF can be used as an inhibitory peptide.

摘要

Syndecan-1是一种表面表达的硫酸乙酰肝素蛋白聚糖,在多种肿瘤类型中上调,并参与肿瘤细胞的迁移和转移。Syndecan-1从细胞表面脱落,剩余的跨膜片段通过γ-分泌酶进行膜内蛋白水解。我们在此表明,这会产生一个细胞质C末端片段(cCTF)。在肺上皮肿瘤A549细胞中,当用硼替佐米阻断其蛋白酶体降解时,内源性产生的cCTF会积累,而γ-分泌酶抑制可阻止这种积累。cCTF过表达抑制了A549细胞的迁移和侵袭。这种抑制作用仅在内源性Syndecan-1存在时可见,而在Syndecan-1缺陷细胞中则未观察到。此外,Syndecan-1 cCTF过表达增加了Src激酶、粘着斑激酶(FAK)和Rho GTP酶的基础激活。这与对纤连蛋白和胶原蛋白G的粘附增加以及桩蛋白向粘着斑的募集增加有关。此外,Syndecan-1 cCTF过表达减少了A549细胞在小鼠体内的肿瘤形成。最后,递送与Syndecan-1 cCTF对应的合成肽可抑制A549细胞迁移,并增加Src和FAK的基础磷酸化。我们的数据表明,Syndecan-1 cCTF通过失调促粘附信号通路在体外和体内拮抗Syndecan-1依赖性肿瘤细胞迁移,并表明cCTF可作为一种抑制性肽。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a26/4741606/8277906843e6/oncotarget-06-31295-g001.jpg

相似文献

5
Cell surface syndecan-1 contributes to binding and function of macrophage migration inhibitory factor (MIF) on epithelial tumor cells.
Biochim Biophys Acta. 2016 Apr;1863(4):717-26. doi: 10.1016/j.bbamcr.2016.02.003. Epub 2016 Feb 4.
6
Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Clin Cancer Res. 2009 May 15;15(10):3416-22. doi: 10.1158/1078-0432.CCR-08-1657.
9
Hierarchy between the transmembrane and cytoplasmic domains in the regulation of syndecan-4 functions.
Cell Signal. 2012 Aug;24(8):1522-30. doi: 10.1016/j.cellsig.2012.03.020. Epub 2012 Apr 4.

引用本文的文献

2
Cleavage of Syndecan-1 Promotes the Proliferation of the Basal-Like Breast Cancer Cell Line BT-549 Via Akt SUMOylation.
Front Cell Dev Biol. 2021 May 25;9:659428. doi: 10.3389/fcell.2021.659428. eCollection 2021.
3
A Disintegrin and Metalloproteinase-Control Elements in Infectious Diseases.
Front Cardiovasc Med. 2020 Dec 16;7:608281. doi: 10.3389/fcvm.2020.608281. eCollection 2020.
5
The Heparan Sulfate Sulfotransferases HS2ST1 and HS3ST2 Are Novel Regulators of Breast Cancer Stem-Cell Properties.
Front Cell Dev Biol. 2020 Sep 25;8:559554. doi: 10.3389/fcell.2020.559554. eCollection 2020.
6
Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1.
Biomolecules. 2020 Sep 23;10(10):1356. doi: 10.3390/biom10101356.
7
Thrombin-cleaved syndecan-3/-4 ectodomain fragments mediate endothelial barrier dysfunction.
PLoS One. 2019 May 15;14(5):e0214737. doi: 10.1371/journal.pone.0214737. eCollection 2019.
8
Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases.
Anal Cell Pathol (Amst). 2018 Jul 29;2018:9432375. doi: 10.1155/2018/9432375. eCollection 2018.
9
Soluble syndecans: biomarkers for diseases and therapeutic options.
Br J Pharmacol. 2019 Jan;176(1):67-81. doi: 10.1111/bph.14397. Epub 2018 Jul 23.
10
Dually modified transmembrane proteoglycans in development and disease.
Cytokine Growth Factor Rev. 2018 Feb;39:124-136. doi: 10.1016/j.cytogfr.2017.12.003. Epub 2017 Dec 22.

本文引用的文献

1
Trans-regulation of Syndecan Functions by Hetero-oligomerization.
J Biol Chem. 2015 Jul 3;290(27):16943-53. doi: 10.1074/jbc.M114.611798. Epub 2015 May 15.
2
Emerging roles of focal adhesion kinase in cancer.
Biomed Res Int. 2015;2015:690690. doi: 10.1155/2015/690690. Epub 2015 Mar 31.
4
Fell-Muir Lecture: Syndecans: from peripheral coreceptors to mainstream regulators of cell behaviour.
Int J Exp Pathol. 2015 Feb;96(1):1-10. doi: 10.1111/iep.12112. Epub 2014 Dec 26.
6
Syndecan-1 regulates vascular smooth muscle cell phenotype.
PLoS One. 2014 Feb 25;9(2):e89824. doi: 10.1371/journal.pone.0089824. eCollection 2014.
7
Protease-mediated ectodomain shedding.
Thorax. 2014 Jul;69(7):682-4. doi: 10.1136/thoraxjnl-2013-204403. Epub 2013 Nov 13.
10
A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.
Eur J Cancer. 2013 May;49(8):2022-33. doi: 10.1016/j.ejca.2012.12.019. Epub 2013 Jan 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验